CMS taps 150 digital health companies, providers for ACCESS Model

CMS selected 150 digital health companies and providers for the 10-year ACCESS chronic care payment model, which begins July 5 and runs through June 30, 2036, with an initial application deadline extended to May 15. The program creates stable, outcome-linked reimbursement for technology used in diabetes, hypertension, CKD, obesity, depression and anxiety, but initial annual payment rates were set below industry expectations at $180-$420 depending on condition, raising margin concerns for high-touch care models. The move could benefit scaled platforms such as Omada Health and Hinge Health, while commercial payers covering 165 million members have agreed to align with the model.

Analysis

The near-term winner is not the broad set of participants, but the few names that can convert low-dollar episodic reimbursement into high-throughput, low-touch utilization. That favors scaled platforms with existing payer/provider distribution, low variable cost per member, and a product set that can be bundled across multiple chronic conditions; it is structurally harder for clinician-heavy models to make the math work at these rates. The second-order effect is a channel-shift: primary care groups and payers now have a reimbursable reason to steer patients into digital care, which should lift referral volume for the best-integrated vendors while commoditizing point solutions.

The market is likely underestimating how punitive the economics are for service-intensive operators. At these payment levels, margin improvement depends less on medical efficacy than on attachment rate, engagement frequency, and the ability to reuse one care workflow across several billed categories; that creates a wedge between “category winners” and “model winners.” Companies that rely on human labor to generate outcomes may see utilization growth but worsening contribution margins, while asset-light platforms can absorb lower unit pricing and still scale.

The key catalyst window is 3-9 months, not immediately: initial partner onboarding, payer contracting, and provider workflow integration will determine whether this becomes a volume story or a margin trap. A reversal would likely come if adoption is slow, outcome attribution is disputed, or payers tighten prior auth/referral gates; any of those would deflate the implied beneficiary counts and expose companies that overhired ahead of the launch. Over a 12-24 month horizon, this could also pressure smaller chronic care startups into consolidation, because larger incumbents can treat ACCESS as customer-acquisition spend while subscale peers cannot.

Key Decisions for Investors

• Long HNGE / short a basket of labor-heavy virtual care and chronic care names for a 6-12 month horizon. Thesis: HNGE can monetize outcomes at scale with lower incremental CAC, while clinician-intensive peers absorb reimbursement compression; target 2-3x the downside-to-upside asymmetry if utilization ramps but margins disappoint.
• Long BOLD as a high-beta beneficiary on a 3-6 month view, but size modestly. The stock has more operating leverage to incremental covered lives than most peers; use a trailing stop if referral volumes fail to inflect by the next two quarters.
• Long CVS and HUM on a 6-12 month horizon as payer-distribution beneficiaries, but prefer relative-value exposure rather than outright beta. The trade works if ACCESS becomes a provider-routing and retention tool inside MA and commercial plans; risk is that integration costs outrun first-year savings.
• Pair long CNC / short OMDA on a 6-9 month horizon. The payer side has optionality from steering and contracting power, while OMDA’s absence from the program suggests it may be missing the most important reimbursement tailwind; risk-reward favors the long leg if the policy becomes sticky.
• Avoid chasing DCGO momentum until evidence of repeatable, low-cost conversion emerges. This is a candidate for a tactical long only after first-wave onboarding data shows utilization without margin dilution; otherwise the launch can become a value trap for service-led models.